nature portfolio

Corresponding author(s):	Magdy M. Mahfouz
Last updated by author(s):	Mar 16, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

_				
C -	トつ	+1	ct	ics
	п		``	11 >

n/a	Confirmed					
	The exact	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
	A stateme	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
	The statist	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
\boxtimes	A descript	A description of all covariates tested				
	🔀 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons					
	A full desc	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
	For null hy Give P value	or null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted we <i>P</i> values as exact values whenever suitable.				
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings					
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
\boxtimes	Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated					
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.					
Software and code						
Policy information about <u>availability of computer code</u>						
D	ata collection	a collection All of the software used in this study is publicly available, and codes are available on request.				

Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Prism files and Excel worksheets were used for analyzing data

The data supporting our findings of this study are included within the article and supplementary information files. The raw genomics sequences and assemblies have been deposited to the National Center for Biotechnology Information under the BioProject accession code PRJNA942452. Mass spectrometry metabolomic data have been deposited to the MetaboLights database with the identifier number MTBLS3320.

Human rese	arch part	icipants		
Policy information	about <u>studies</u>	involving human research participants and Sex and Gender in Research.		
Reporting on sex and gender Our s		Our study does not include any human research participants.		
Population chara		NA		
		NA		
_	Ethics oversight NA Note that full information on the approval of the study protocol must also be provided in the manuscript.			
TVOICE CHAR TAIL THIOTHIG	ation on the app	oval of the study protector must use be provided in the manageripe.		
Field-spe	ecific re	eporting		
· · · · · · · · · · · · · · · · · · ·		is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
X Life sciences		Behavioural & social sciences		
	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life scier	nces st	udy design		
All studies must dis	sclose on these	points even when the disclosure is negative.		
Sample size		me and ionome profiling, we used rice grains of 24 black, 35 red and four brown Asian rice. For genome sequencing, we a samples from the leaf of 51 individual plants (24 black, and 27 red).		
Data exclusions	No data was e	excluded.		
Replication	several individ	me and ionome profiling, 20 grains were grinded for each verity that were collected from a batch of grains collected from dual plants, Three independent technical replicates were performed by Metabolon. For genome sequencing, a single seed per own for DNA collection.		
Randomization		selected randomly and sample injection was also randomized in the UPLC–MS, and ICP–MS platforms. CRISPR-edited and wild vere selected in a random manner for harvesting and phenotyping.		
Blinding	Blinding is not	Blinding is not common practice for this type of experiments.		
	_			
Reportin	g for s	pecific materials, systems and methods		
		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, by your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & over	norimontal	systems Methods		
		n/a Involved in the study		
Antibodies		ChIP-seq		
Eukaryotic cell lines		Flow cytometry		

Palaeontology and archaeology Animals and other organisms

Dual use research of concern

Clinical data